ES2139578T3 - Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn. - Google Patents

Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.

Info

Publication number
ES2139578T3
ES2139578T3 ES91911934T ES91911934T ES2139578T3 ES 2139578 T3 ES2139578 T3 ES 2139578T3 ES 91911934 T ES91911934 T ES 91911934T ES 91911934 T ES91911934 T ES 91911934T ES 2139578 T3 ES2139578 T3 ES 2139578T3
Authority
ES
Spain
Prior art keywords
rna
modification
compositions
procedure
protective structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91911934T
Other languages
English (en)
Inventor
Brenda F Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2139578T3 publication Critical patent/ES2139578T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN LOS METODOS PARA LOGRAR UN TRATAMIENTO TERAPEUTICO DE LAS ENFERMEDADES Y PARA REGULAR LA EXPRESION DE LOS GENES EN SISTEMAS EXPERIMENTALES BIOLOGICOS A TRAVES DE LA MODIFICACION DE LA ESTRUCTURA 5'' CAP DE LOS ACIDOS RIBONUCLEICOS TERMINADOS. LA MODIFICACION O SUPRESION DE LA ESTRUCTURA 5'' CAP SE LOGRA, DE ACUERDO CON LAS REALIZACIONES PREFERIDAS, UTILIZANDO LOS COMPUESTOS INVERSOS QUE SON COMPLEMENTARIOS DEL TERMINO 5'' DEL ARN TERMINADO Y TIENEN UNIDOS A ELLOS SISTEMAS REACTIVOS EXPLICITAMENTE DISEÑADOS PARA LA MODIFICACION QUIMICA DE O LAS REACCIONES DE DISOCIACION CON LA ESTRUCTURA 5'' CAP DEL ARN.
ES91911934T 1990-05-23 1991-05-22 Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn. Expired - Lifetime ES2139578T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52759990A 1990-05-23 1990-05-23

Publications (1)

Publication Number Publication Date
ES2139578T3 true ES2139578T3 (es) 2000-02-16

Family

ID=24102143

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91911934T Expired - Lifetime ES2139578T3 (es) 1990-05-23 1991-05-22 Composiciones y procedimiento para modular la actividad del arn mediante la modificacion de la estructura protectora 5' del arn.

Country Status (15)

Country Link
EP (1) EP0531447B1 (es)
JP (1) JPH06500075A (es)
KR (1) KR960004931B1 (es)
AT (1) ATE186464T1 (es)
AU (1) AU649458B2 (es)
BR (1) BR9106486A (es)
CA (1) CA2083377C (es)
DE (1) DE69131773T2 (es)
DK (1) DK0531447T3 (es)
ES (1) ES2139578T3 (es)
FI (1) FI925210A7 (es)
GR (1) GR3032457T3 (es)
HU (1) HUT63568A (es)
NO (1) NO924309L (es)
WO (1) WO1991017755A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
IL114235A0 (en) * 1994-07-14 1995-10-31 Schering Ag Oligonucleotide conjugates and processes for noninvasive diagnosis utilizing the same
US6380169B1 (en) * 1994-08-31 2002-04-30 Isis Pharmaceuticals, Inc. Metal complex containing oligonucleoside cleavage compounds and therapies
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
WO2001062981A1 (en) * 2000-02-25 2001-08-30 Montclair Group Platform for the discovery of the bacterial genes involved in rna modification
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
HUT63170A (en) * 1990-01-11 1993-07-28 Isis Pharmaceuticals Inc Process and composition for detecting and modifying rna activity and gene expression

Also Published As

Publication number Publication date
DK0531447T3 (da) 2000-03-27
EP0531447A4 (en) 1993-08-11
FI925210L (fi) 1992-11-17
DE69131773D1 (de) 1999-12-16
NO924309D0 (no) 1992-11-09
FI925210A0 (fi) 1992-11-17
EP0531447A1 (en) 1993-03-17
GR3032457T3 (en) 2000-05-31
CA2083377A1 (en) 1991-11-24
AU649458B2 (en) 1994-05-26
KR930700118A (ko) 1993-03-13
WO1991017755A1 (en) 1991-11-28
EP0531447B1 (en) 1999-11-10
CA2083377C (en) 2002-11-26
FI925210A7 (fi) 1992-11-17
HU9203659D0 (en) 1993-04-28
HUT63568A (en) 1993-09-28
DE69131773T2 (de) 2000-03-02
ATE186464T1 (de) 1999-11-15
JPH06500075A (ja) 1994-01-06
AU8080291A (en) 1991-12-10
BR9106486A (pt) 1993-05-25
KR960004931B1 (ko) 1996-04-18
NO924309L (no) 1992-11-09

Similar Documents

Publication Publication Date Title
DE59209658D1 (de) Pharmazeutische zusammensetzung zur wund-, narben- und keloidbehandlung
GEP20033145B (en) Stem Cell Factor
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
ATE196600T1 (de) Kosmetische zubereitungen enthaltend extrakte von phyllanthus emblica und centella asiatica und/oder bacopa monnieri
ES2116986T3 (es) Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello.
HU883981D0 (en) Process for the production of medical preparations with antiviral or antibacterial effect
DE3877529D1 (de) Herstellung von hoch-gereingtem menschlichen faktor ix sowie anderem plasmaproteinkonzentrat und dessen therapeutische verwendung.
ES2102921T3 (es) Utilizacion de derivados de la hormona estimuladora de los melanocitos de tipo alfa para estimular el crecimiento de los cabellos.
MY110734A (en) Improvements in or relating to dioic acids.
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
DK254887A (da) Salve til behandling af hudsygdomme
ATE71294T1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
ATE78171T1 (de) Gangliosidgemisch zur verwendung als therapeutisches hilfsmittel zur schmerzunterdrueckung bei peripheren neuropathien.
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
MY101718A (en) Medicated cosmetic compositions
DK137589A (da) Salicylsyreholdigt middel til behandling af hudsygdomme
ATE77048T1 (de) Bioemulgatoren enthaltende kosmetische und pharmazeutische zusammensetzungen.
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
ES8304058A1 (es) Un procedimiento para la preparacion del acido 3,7,11,15-tetrametil-2,4,6,10,14-hexadecapentaenoico.
ES2006121A6 (es) Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
DE69031569D1 (de) Podophyllotoxinzubereitung enthaltend triglyceride
ES2042724T3 (es) Una composicion terapeutica o profilactica.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 531447

Country of ref document: ES